The forecast data indicates a steady increase in the number of multidrug-resistant tuberculosis (MDR-TB) cases started on treatment in India from 71,360 cases in 2024 to 84,260 cases in 2028 (in thousands). The year-on-year growth rate shows an average increase of about 4% over this period. Assuming 2023 had a similar value to 2024, the five-year CAGR is approximated at 4.3%.

Future trends to watch for include:

Advancements in treatment options and their impact on reducing MDR-TB incidence.
Policy changes and health initiatives aimed at combatting TB more effectively in India.
Emerging patterns in drug resistance that could affect treatment efficacy.